Table 1. Clinical characteristics of the study sample in each randomized clinical trial.
| CH status | Response status | Age | Sex | Smoking history | |||
|---|---|---|---|---|---|---|---|
| Yes (%) | Non-responders (%) | Median (range) | Male (%) | Never (%) | Previous (%) | Current (%) | |
| Anti-PD-L1 arm (N) | |||||||
| FIR (85) | 17 (20.0) | 61 (71.8) | 66 (41–85) | 49 (57.6) | 9 (10.6) | 62 (72.9) | 14 (16.5) |
| POPLAR (74) | 12 (16.2) | 57 (77.0) | 61 (42–82) | 48 (64.9) | 10 (13.5) | 51 (68.9) | 13 (17.6) |
| IMpower110 (85) | 5 (5.9) | 57 (67.1) | 64 (46–81) | 55 (64.7) | 11 (12.9) | 55 (64.7) | 19 (22.4) |
| IMpower150 (363) | 54 (14.9) | 167 (46.0) | 63 (31–83) | 228 (62.8) | 65 (17.9) | 207 (57.0) | 91 (25.1) |
| IMpower131 (250) | 35 (14.0) | 95 (38.0) | 65 (25–85) | 199 (79.6) | 24 (9.6) | 158 (63.2) | 68 (27.2) |
| Overall (857) | 123 (14.4) | 437 (51.0) | 64 (25–85) | 579 (67.6) | 119 (13.9) | 533 (62.2) | 205 (23.9) |
| Comparator arm (N) | |||||||
| FIR (NA) | NA | NA | NA | NA | NA | NA | NA |
| POPLAR (74) | 13 (17.6) | 53 (71.6) | 61.0 (36–80) | 36 (48.6) | 17 (23.0) | 47 (63.5) | 10 (13.5) |
| IMpower110 (78) | 8 (10.3) | 48 (61.5) | 65.0 (44–84) | 52 (66.7) | 14 (17.9) | 49 (62.8) | 15 (19.2) |
| IMpower150 (182) | 26 (14.3) | 92 (50.5) | 63.0 (31–87) | 108 (59.3) | 33 (18.1) | 107 (58.8) | 42 (23.1) |
| IMpower131 (90) | 11 (12.2) | 47 (52.2) | 65.0 (45–79) | 70 (77.8) | 5 (5.6) | 55 (61.1) | 30 (33.3) |
| Overall (424) | 58 (13.7) | 240 (56.6) | 63.5 (31–87) | 266 (62.7) | 69 (16.3) | 258 (60.8) | 97 (22.9) |
| Both arms=1281 | 181 (14.1) | 677 (52.8) | 64 (25–87) | 845 (66) | 188 (14.7) | 791 (61.7) | 302 (23.6) |
CH, clonal hematopoiesis; PD-L1, programmed death ligand-1.